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Background: Glioblastoma (GBM) is an aggressive disease associated with poor survival. It is essential to account
for the complexity of GBM biology to improve diagnostic and therapeutic strategies. This complexity is best
represented by the increasing amounts of profiling (“omics”) data available due to advances in biotechnology. The
challenge of integrating these vast genomic and proteomic data can be addressed by a comprehensive systems
modeling approach.
Methods: Here, we present an in silico model, where we simulate GBM tumor cells using genomic profiling data.
We use this in silico tumor model to predict responses of cancer cells to targeted drugs. Initially, we probed the
results from a recent hypothesis-independent, empirical study by Garnett and co-workers that analyzed the sensitivity
of hundreds of profiled cancer cell lines to 130 different anticancer agents. We then used the tumor model to predict
sensitivity of patient-derived GBM cell lines to different targeted therapeutic agents.
Results: Among the drug-mutation associations reported in the Garnett study, our in silico model accurately predicted
~85% of the associations. While testing the model in a prospective manner using simulations of patient-derived GBM
cell lines, we compared our simulation predictions with experimental data using the same cells in vitro. This analysis
yielded a ~75% agreement of in silico drug sensitivity with in vitro experimental findings.
Conclusions: These results demonstrate a strong predictability of our simulation approach using the in silico tumor
model presented here. Our ultimate goal is to use this model to stratify patients for clinical trials. By accurately
predicting responses of cancer cells to targeted agents a priori, this in silico tumor model provides an innovative
approach to personalizing therapy and promises to improve clinical management of cancer.
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Cancer remains a major unmet clinical need despite ad-
vances in clinical medicine and cancer biology. Glioblastoma
(GBM) is the most common type of primary adult brain
cancer, characterized by infiltrative cellular proliferation,
angiogenesis, resistance to apoptosis, and widespread gen-
omic aberrations. GBM patients have poor prognosis, with a
median survival of 15 months [1]. Molecular profiling and* Correspondence: skesari@ucsd.edu
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unless otherwise stated.genome-wide analyses have revealed the remarkable gen-
omic heterogeneity of GBM [2,3]. Based on tumor profiles,
GBM has been classified into four distinct molecular sub-
types [4]. However, even with existing molecular classifica-
tions, the high intertumoral heterogeneity of GBM makes it
difficult to predict drug responses a priori. This is even
more evident when trying to predict cellular responses to
multiple signals following combination therapy. Our ration-
ale is that a systems-driven computational approach will
help decipher pathways and networks involved in treatment
responsiveness and resistance.
Though computational models are frequently used in
biology to examine cellular phenomena, they are nottd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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However, models have previously been used to estimate
tumor infiltration following surgery [7] or changes in
tumor density following chemotherapy in brain cancers
[8]. More recently, brain tumor models have been used
to determine the effects of conventional therapies in-
cluding chemotherapy and radiation [5]. Brain tumors
have also been studied using an agent-based modeling
approach [9]. Multiscale models that integrate hierarch-
ies in different scales are being developed for application
in clinical settings [10]. Unfortunately, none of these models
have been successfully translated into the clinic so far. It is
clear that innovative models are required to translate data
involving biological networks and genomics/proteomics into
optimal therapeutic regimens. To this end, we present a de-
terministic in silico tumor model that can accurately predict
sensitivity of patient-derived tumor cells to various targeted
agents.
Methods
Description of In Silico model (Version 7.3 Cellworks)
We performed simulation experiments and analyses using
the predictive tumor model – a comprehensive and dy-
namic representation of signaling and metabolic pathways
in the context of cancer physiology. This in silico model
includes representation of important signaling pathways
implicated in cancer such as growth factors such as EGFR,
PDGFR, FGFR, c-MET, VEGFR and IGF-1R; cytokine and
chemokines such as IL1, IL4, IL6, IL12, TNF; GPCR medi-
ated signaling pathways; mTOR signaling; cell cycle
regulations, tumor metabolism, oxidative and ER stress,
representation of autophagy and proteosomal degradation,
DNA damage repair, p53 signaling and apoptotic cascade.
The current version of this model includes more than
4,700 intracellular biological entities and ~6,500 reactions
representing their interactions, regulated by ~25,000
kinetic parameters. This comprises a comprehensive
and extensive coverage of the kinome, transcriptome,
proteome and metabolome. Currently, we have 142 kinases
and 102 transcription factors modeled in the system.
Model development
We built the basic model by manually curating data from
the literature and aggregating functional relationships be-
tween proteins. The detailed procedure for model devel-
opment is explained in Additional file 1 (Section 2) using
the example of the epidermal growth factor receptor
(EGFR) pathway block (Additional file 1: Figure S1 and
Figure S2). We have also presented examples of how
the kinetic parameters are derived from experimental
data, in Additional file 1: (Section 2). We have validated
the simulation model prospectively and retrospectively, at
phenotype and biomarker levels using extensive in vitro
and in vivo studies [11-20].Disease phenotype definitions
Disease phenotype indices are defined in the tumor
model as functions of biomarkers involved. Proliferation
Index is an average function of the active CDK-Cyclin
complexes that define cell cycle check-points and are
critical for regulating overall tumor proliferation poten-
tial. The biomarkers included in calculating this index
are: CDK4-CCND1, CDK2-CCNE, CDK2-CCNA and
CDK1-CCNB1. These biomarkers are weighted and their
permutations provide an index definition that gives max-
imum correlation with experimentally reported trend for
cellular proliferation (based on literature).
We also generate a Viability Index based on 2 sub-
indices: Survival Index and Apoptosis Index. The bio-
markers constituting the Survival Index include: AKT1,
BCL2, MCL1, BIRC5, BIRC2 and XIAP. These biomarkers
support tumor survival. The Apoptosis Index comprises:
BAX, CASP3, NOXA and CASP8. The overall Viability
Index of a cell is calculated as a ratio of Survival Index/
Apoptosis Index. The weightage of each biomarker is
adjusted so as to achieve a maximum correlation with
the experimental trends for the endpoints (based on
literature).
In order to correlate the results from experiments
such as MTT Assay, which are a measure of metabolic-
ally active cells, we have a ‘Relative Growth’ Index that is
an average of the Survival and Proliferation Indices.
The percent change seen in these indices following a
therapeutic intervention helps assess the impact of that
particular therapy on the tumor cell. A cell line in which
the Proliferation/Viability Index decreases by <20% from
the baseline is considered resistant to that particular
therapy.
Creation of cancer cell line and its variants
To create a cancer-specific simulation model, we start
with a representative non-transformed epithelial cell as
control. This cell is triggered to transition into a neo-
plastic state, with genetic perturbations like mutation
and copy number variation (CNV) known for that spe-
cific cancer model. We also created in silico variants for
cancer cell lines, to test the effect of various mutations
on drug responsiveness. We created these variants by
adding or removing specific mutations from the cell line
definition. For example, DU145 prostate cancer cells nor-
mally have RB1 deletion. To generate a variant of DU145
with wild-type RB1 (WT), we retained the rest of its muta-
tion definition except for the RB1 deletion, which was
converted to WT RB1 (Additional file 1).
Simulation of drug effect
To simulate the effect of a drug in the in silico tumor model,
the targets and mechanisms of action of the drug are deter-
mined from published literature. The drug concentration is
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tabolism and Excretion).
Creation of simulation avatars of patient-derived GBM cell
lines
To predict drug sensitivity in patient-derived GBM cell
lines, we created simulation avatars (in silico profiles) for
each cell line as illustrated in Figure 1B. First, we simu-
lated the network dynamics of GBM cells by using ex-
perimentally determined expression data (Additional file
1: Table S1; Additional file 1: Section 7). Next, we over-
lay tumor-specific genetic perturbations on the control
network, in order to dynamically generate the simulation
avatar. For instance, the patient-derived cell line SK987
is characterized by overexpression of AKT1, EGFR, IL6, and
PI3K among other proteins and knockdown of CDKN2A,
CDKN2B, RUNX3, etc. (Additional file 1: Table S1). After
adding this information to the model, we further optimized
the magnitude of the genetic perturbations, based on
the responses of this simulation avatar to three mo-
lecularly targeted agents: erlotinib, sorafenib and dasa-
tinib. The response of the cells to these drugs (from
in vitro experimental data) was used as an “alignment
data set”. In this manner, we used “alignment drugs”
(erlotinib, sorafenib, and dasatinib) to optimize the
magnitude of genetic perturbation in the trigger files
and their impact on key pathways targeted by these
drugs. For example, most GBM cell lines demonstratedFigure 1 Simulation workflow for in silico tumor model. A, This illustra
analysis of gene mutation-drug sensitivity association reported in the Gar
Untriggered state is simulated for 50,000 seconds to allow the biologica
mutation data is introduced and simulated for an additional 1,25,000 sec
drug into the system by perturbing the target reaction nodes and simul
percent change in the indices for cell survival. B, This schematic demonstrates
patient-derived GBM cell line profiles in silico. The key steps involved in develo
Input profiling data reporting relative expression of the different proteins in th
experimental data on drugs used for alignment of the network (erlotinib, sora
and in vitro testing.dominance of EGFR signaling as they had gains in copy
number of EGFR gene. Hence the effect of EGFR in-
hibitor would be a good indicator for the relative dom-
inance of this signaling pathway. This is illustrated in
further details in Additional file 1 using an example of
two cell line profiles that have EGFR over-expression
but differential response to EGFR inhibitor. Similarly, so-
rafenib helped determine and align with MEK/ERK activa-
tion, while dasatinib with activation of SRC signaling.
Simulation protocol
The simulation protocol included 3 states:
1. Control State – The in silico model was simulated
for 50,000 seconds, during which the different
biological entities (called species) attain a
steady-state concentration. This concentration
depends on the balance between the rate of
reaction nodes producing the species and the
reaction nodes utilizing/degrading the species.
This is an untriggered system and is representative of
a non-transformed epithelial cell.
2. Disease State – At 50,000 seconds simulation time,
we introduced the mutation data (specific to
patient-derived GBM cell lines to be created) and
simulated for an additional 1,25,000 seconds. During
this time, the system attained a new steady state that
aligns to the network dynamics of the cell line.tion depicts a representative simulation protocol used for retrospective
nett study. The simulation protocol included 3 states: Control or
l entities to attain a steady-state concentration. At 50,000 seconds,
onds to attain Disease state. For Drug-treated state, we introduce a
ate the model for 2,00,000 seconds. At the end of this state, we calculate
the simulation workflow for creation, optimization and testing of
ping the simulation avatars of the patient-derived GBM cell lines include:
e cell lines; Iterative testing and alignment of simulation avatars to match
fenib and dasatinib); Locking the simulation avatars; In silico predictions
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simulation run time of 1,25,000 seconds for Disease
State, we introduced the drug into the system by
perturbing the target reaction nodes as explained
above. We then simulated the model further for
2,00,000 seconds (drug treatment). A percent change
in the indices for cell survival (described earlier)
indicates the therapeutic potential of the drug.
Iterative simulations with varying concentrations of
the drug generate dose-response curves from which
IC50 values can be determined.
Figure 1A is a schematic of the representative simula-
tion protocol that we used for the retrospective analysis
of gene mutations-drug effects reported in the study by
Garnett and co-workers. Figure 1B illustrates the work-
flow for simulation studies on patient-derived GBM cell
lines. For the patient-derived GBM cell line predictions,
we prospectively compared in silico responses to experi-
mentally obtained results (in vitro data from patient-
derived GBM cell lines) and determined corroboration
between in silico and in vitro data. As per the dose-
response plots generated by in silico predictions, a cell
line was considered sensitive to a drug if it demon-
strated >20% decrease in relative growth. The 20% thresh-
old was used for both in silico predictions and for in vitro
experimental data.
Patient-derived glioblastoma cell lines
Fresh human glioblastoma samples were acquired from
brain tumor patients undergoing clinically indicated sur-
gery (University of California San Diego Human Subjects
Protocol) and cultured as previously reported [21,22].
GBM4 and 8 cells were a kind gift from C. David James
(University of California San Francisco). Briefly, the disso-
ciated tissue was washed, filtered through a 30 μm mesh
and plated onto ultra-low adherence flasks at a concentra-
tion of 500,000 to 1,500,000 viable cells/ml. The stem cell
isolation medium included human recombinant EGF
(20 ng/ml), human bFGF (10 ng/ml) and heparin
(2 μg/ml). Sphere cultures were passaged by dissoci-
ation using Acutase (Sigma), washed, resuspended in
neural stem cell culture medium (#05750, Stemcell Tech-
nologies), and plated on ultra low-adherence 96 well plates
at 2000 cells per well for all subsequent drug testing. We
characterized all patient-derived glioblastoma lines using
histopathologic and integrated genomic analyses. The
glioblastoma lines were profiled using the Affymetrix
Gene Chip Human Gene 1.0 ST Array.
Drug screening
Drug screens were performed on patient-derived GBM
cell lines plated at 2000 cell per well in 96-well microtiter
plates, incubated overnight. After 72 hours of incubationwith drugs, cell viability was quantified by the Alamar Blue
assay. Briefly, after incubation, Alamar Blue (#BUF012B,
AbDSerotec) was added directly to the culture medium,
and the fluorescence measured at 560/90 to determine the
number of viable cells (Infinite M200, Tecan Group Ltd.).
Results
Our study involved a retrospective component where we
predicted gene mutations – drug sensitivity associations
defined in a recent hypothesis-independent study [23].
In addition, we predicted sensitivity of our profiled
patient-derived GBM cell lines to targeted agents and
compared these in silico predictions to in vitro experi-
mental data.
Retrospective validation of in Silico tumor model
In the first part of the study, we evaluated the ability of
the in silico tumor model to predict drug responses that
were reported in the study by Garnett and colleagues
[23]. A comparison of our predictions with the associa-
tions reported in the Garnett study indicated the pre-
dictive capability of our in silico tumor model.
Our modeling library has definitions for 45 of the 639
cell lines used in this study (Additional file 1: Table S2)
and supports 70 of the 130 drugs studied (Additional file 1:
Table S3). Further, we can represent 51 of the 84 genes
screened for mutations (Additional file 1: Table S4). Of the
448 significant gene mutation-drug response associations
reported, our in silico model was able to accurately predict
22 of the 25 testable associations from the Garnett study
(>85% agreement; Additional file 1: Table S5). The gene
mutation–drug response correlations from the Garnett
study that are currently not supported by the system are
listed in Additional file 1: Table S6. From the 25 gene mu-
tation–drug response associations tested from the Garnett
study (Additional file 1: Table S5), a few examples of the
correlations are explained below. Figure 1A depicts a rep-
resentative schematic of this retrospective analysis using
the simulation (in silico tumor model).
BRAF Mutations and Drug Sensitivity
The Garnett study showed that cells with BRAF mutation
were sensitive to the MEK1/2 inhibitor AZD2644 [23]. To
examine this association, we modeled cancer cell variants
with wild-type BRAF in silico. Modeling data showed that
cells with wild-type BRAF were resistant to AZD6244,
when compared to the parent tumor cells with mutant
BRAF. Thus, BRAF mutation conferred sensitivity to the
MEK1/2 inhibitor in silico; this prediction validates the
finding reported in the Garnett study (Figure 1A). 40-60%
melanoma patients carry BRAF mutations that activate
MAPK signaling [24,25] and this association could have
therapeutic implications for the treatment of patients with
BRAF mutant melanoma.
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Kinase inhibitors
The Garnett study showed that cells with BRAF muta-
tion were sensitive to the MEK1/2 inhibitor AZD2644
[23]. To examine this association, we created cancer cell
variants with wild-type BRAF in the in silico model.
Simulation data showed that cells with wild-type BRAF
were resistant to AZD6244, when compared to cells with
mutant BRAF. Thus, BRAF mutation conferred sensitivity
to the MEK1/2 inhibitor; this validates the finding re-
ported in the Garnett study (Figure 2A). 40-60% melan-
oma patients carry BRAF mutations that activate MAPK
signaling [24,25]. This association tested in Figure 2A may
have therapeutic implications for the treatment of patients
with BRAF mutant melanoma.
ERBB2 (HER2) amplification is a biomarker for sensi-
tivity to EGFR-family inhibitors [26]. In the in silicoFigure 2 Retrospective analysis tests in silico predictions of gene mut
reported in the Garnett study were tested in a blinded manner using our i
reported in the Garnett study. A, We created wild-type BRAF variants of fou
and compared the effect of MEK1/2 inhibitor AZD2644 on these cell lines a
demonstrated that BRAF mutation increases sensitivity to AZD6244. B, We
mutant BRAF and tested for sensitivity to the EGFR2 family kinase inhibito
C, Similarly, when four cell lines (AGS, H1437, MKN1 and MKN45) were te
increases sensitivity to lapatinib. D, We generated cell lines with wild-typ
AGS, H358 and HT29 cell lines). MET over-expression increases sensitivitymodel, we tested for sensitivity to EGFR2 family inhibi-
tors, lapatinib and BIBW2992. Specifically, we examined
sensitivity of cancer cells in the presence of mutations
and/or over-expression of BRAF, CDH1, ERBB2, CCND1
and MET. These predictions from simulations were com-
pared with results obtained in the Garnett study and the
predictive capability of our model was determined.
In silico predictions indicate that BRAF mutation de-
creases sensitivity of cells to lapatinib (Figure 2B), whereas
CDH1 mutant lines demonstrated higher sensitivity to
lapatinib when compared to variants with wild-type
CDH1 (Figure 2C). Further, cMET over-expression showed
increased sensitivity to lapatinib, as indicated by decrease
in viability in cells with cMET over-expression (Figure 2D).
Additionally, ERBB2 and CCND1 over-expression cor-
related positively with lapatinib sensitivity (Additional
file 1: Table S5). In all these simulation experimentsations and sensitivity to EGFR family inhibitors. Associations
n silico model and predictions obtained were compared to results
r cancer cell lines – COLO205, HT29, MDAMB231 and U266 in silico
nd on corresponding parent lines expressing mutant BRAF. Our data
simulated three cell lines – H1650, H1975 and SW48 with wild-type or
r, lapatinib. BRAF mutation decreases sensitivity of cells to lapatinib.
sted for sensitivity to lapatinib, we observed that CDH1 mutation
e or MET over-expression and tested the effect of lapatinib (A549,
to lapatinib.
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corroborated with associations reported in the Garnett
study.
CDKN2A mutation and drug sensitivity
The Garnett study reported associations between tumor
suppressor gene mutations and several anti-cancer drugs.
We tested these associations in our in silico tumor model.
In the in silico analysis, cells harboring wild-type CDKN2A
were resistant to erlotinib whereas CDKN2A mutation was
associated with erlotinib sensitivity (Figure 3A). Similarly,
cell lines with mutant CDKN2A showed increased sensitiv-
ity to dasatinib (Figure 3B), bortezomib (Figure 3C), and to
the CDK4/6 inhibitor PD0332991 (Figure 3D). These pre-
dictions/analyses from our simulation corroborated accur-
ately with data from the Garnett study.
Other gene mutation-drug response associations exam-
ined in our simulation models are illustrated in Additional
file 1: Table S5. In addition, Additional file 1: Table S6 listsFigure 3 Retrospective analysis evaluates CDKN2A mutation – drug r
modeling, we tested the role of the tumor-suppressor protein CDKN2A on
those reported in the Garnett study. A, Cells expressing mutant CDKN2A an
for four lines – BxPC3, H1437, H1650 and SW48. CDKN2A mutation increase
B, Cells with mutant CDKN2A were more sensitive to dasatinib than cells w
HT29, H1437 and SW48 cell lines with mutant CDKN2A were sensitive to b
mutant cells BxPC3, H1437, H1975 and HT29 also showed higher sensitivitycorrelations between gene mutations and drug responses
reported in the Garnett study, which are currently not
supported by our modeling technology. In spite of these
limitations, we obtained ~85% agreement of our simula-
tion data with findings reported by Garnett [23].
Prospective evaluation of tumor model – patient-derived
GBM cell lines
Identifying drug sensitivities in tumors/cancers with different
mutations is important for designing individualized therapies
for cancer. To this end, we created in silico avatars of 8
patient-derived GBM cell lines using genomic data (Methods
and Additional file 1: Table S1) and predicted their sensitivity
to various targeted therapeutic agents. We then tested these
in silico predictions prospectively by comparing then with
experimental data obtained by in vitro testing on the same
patient-derived GBM cell lines (Figure 1B).
The patient-derived GBM cell lines were obtained from
patient tumors resected surgically and cultured in vitroesponse association by in silico modeling. Using simulation
sensitivity to different inhibitors and compared these predictions to
d their wild-type variants were simulated in the in silico tumor model
d sensitivity of cells to erlotinib when compared to wild-type CDKN2A.
ith wild-type CDKN2A (A549, BxPC3, HCT116 and H460). C, COLO205,
ortezomib more than cells expressing wild-type variants. D, CDKN2A
to CDK4-Cyclin D1 inhibitor PD0332991 over the CDKN2A WT variants.
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Affymetrix Gene Chip Human Gene 1.0 ST Array. Using
whole-exome sequencing, we recently tested the validity
of these cells (maintained in cultures) for development
and testing of personalized targeted therapies, based on
their accurate representation of the original tumor profiles
[27]. We have designated the different patient-derivedFigure 4 In silico modeling analysis and experimental in vitro data for
response data for erlotinib with percent change in viability. Cells showing d
drug. B, In vitro experimental results for effect of 1 μM erlotinib on viability
using Alamar Blue assay. C, D, Predictive and experimental data for sorafen
tested in vitro at 1 μM. Dose-response curves for in silico data demonstrat
sorafenib and sunitinib on the viability of profiled patient-derived GBM cGBM cell lines as: GBM4, GBM8, SK102, SK262, SK429,
SK748, SK987 and SK1035.
After generating in silico profiles of these cells, we opti-
mized these simulation avatars in terms of strength of func-
tional effect of the mutation on key pathways such as EGFR,
RAS and Src/PI3K. The rationale for this optimization is
that expression data on these cells does not provide andrug responsiveness to 3 alignment drugs. A, Predictive dose
ecrease in viability of 20% or greater are considered sensitive to the
in patient-derived GBM cell lines; viability was determined at 72 h
ib. E, F, Predictive and experimental data for dasatinib. All drugs were
e the effects of increasing concentrations of the drugs – erlotinib,
ell lines in the simulation model.
Figure 5 (See legend on next page.)
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Figure 5 In silico modeling and experimental in vitro data for drug responsiveness to tyrosine kinase inhibitors. This figure
demonstrates in silico predictions of sensitivity and in vitro viability (respectively) in response to treatment with tyrosine kinase inhibitors:
A, B, lapatinib, C, D, nilotinib, E, F, Imatinib and G, H, Sunitinib. Cells were exposed in vitro to 1 μM tyrosine kinase inhibitors for 72 h and
viability determined using Alamar Blue assay. The dose-response for in silico predictions is generated by iterative simulations with increasing
concentrations of the drug in the model and the viability index is calculated. Cells showing decrease in viability of 20% or greater are considered
sensitive to the drug.
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pathways. In order to interrogate this information on the
pathways that play a dominant role in each tumor line (such
as EGFR, RAS, PI3K, etc.), we used 3 anti-cancer agents (er-
lotinib, sorafenib and dasatinib) targeting these pathways.
This will achieve “alignment” and train the simulation ava-
tars for further analyses (details in Additional file 1). The
alignment for these 3 drugs could be best achieved in the
following cell lines: GBM8, SK262, SK429, SK748, and
SK1035. In cell lines GBM4 and SK987, there was a mis-
match for sorafenib where the predictive trends were re-
versed. GBM4 was sensitive to sorafenib experimentally but
our in silico predictions showed it to be resistant; SK987
was resistant experimentally but sensitive in predictive re-
sults. Similarly, the experimental trend for SK102 resistance
to dasatinib could not be met predictively. Correlation of
predictive trends with alignment drugs is shown in Figure 4
A-F.
Predictions obtained by simulation modeling are pre-
sented as dose-response plots for viability; decrease in
viability of >20% was considered as sensitive. Experimen-
tally, viability was determined by Alamar blue assay, in
response to 1 μM concentration of respective inhibitors
at 72 h. These data represent viability as mean values
from triplicate samples.
We tested ten anti-cancer drugs in silico on the simu-
lation avatars of the 8 patient-derived GBM cell lines in
a blinded prospective study. These simulations generated
predictions that we compared with in vitro experimental
data (Additional file 1: Table S7A-D). Of the 80 in silico
predictions, 61 (76.25%) predictions showed agreement
with in vitro experimental results. Analysis of drug
sensitivity correlation for all 8 GBM patient-derived
cell lines, for all the 13 drugs is summarized in Additional
file 1: Table S7. Figures 5A-H and 6A-H show a drug-
wise comparison of in silico predictions (dose-response
curves) and in vitro experimental results generated
with testing 1 μM concentration of each drug on these
cell lines.
Effect of tyrosine kinase inhibitors on patient-derived
GBM cells
For the EGFR family inhibitor lapatinib, simulation stud-
ies predicted SK429, SK748 and SK1035 to be resistant,
which were confirmed by in vitro data. Similarly, model-
ing predicted GBM8, SK102, SK262 and SK987 to besensitive and these predictions were in agreement with
experimental data (Figure 5A and B). However, modeling
predicted GBM4 to be resistant to lapatinib while in vitro
data showed GBM4 to be highly sensitive to lapatinib
(Figure 5B). For the tyrosine kinase inhibitor nilotinib,
the model predicted GBM8 to be sensitive while all the
other profiles to be resistant (Figure 5C). In vitro stud-
ies demonstrated that GBM8 was indeed sensitive to
nilotinib as predicted, but there was a mismatch with
the experimental results for two lines – SK262 and
SK1035. Experimentally, SK262 was found to be sensi-
tive, whereas SK1035 was on the borderline of sensitiv-
ity and resistance (Figure 5D). For imatinib, simulation
predicted that all GBM lines except GBM8 were resist-
ant (Figure 5E). The experimental results corroborated
with this in silico prediction (Figure 5F). Sunitinib was
the other multi-tyrosine kinase inhibitor tested. Our
simulation predicted GBM8, SK102 and SK987 to be
sensitive to sunitinib; however, only GBM8 was found
to be sensitive in vitro. SK262 was predicted to be re-
sistant to sunitinib but in vitro data found it to be moder-
ately sensitive. On the other hand, GBM4, SK429, SK748
and SK1035 were found to be resistant in both simulation
and experimental data (Figure 5G-H).
Effect of other drugs on patient-derived GBM cells
Besides the tyrosine kinase inhibitors, correlation be-
tween in silico predictions and experimental results for
the 8 patient-derived GBM cell lines was also tested for
drugs such as pitavastatin (HMG CoA reductase inhibi-
tor), everolimus (mTOR inhibitor), celecoxib (COX2 in-
hibitor) and bortezomib (proteasome inhibitor) (Figure 6
A-H). For bortezomib, all profiles were predicted to be
sensitive and these predictions matched with in vitro ex-
perimental results (Figure 6A and B). For everolimus,
in vitro results were in agreement with simulation pre-
dictions for all lines except SK429 (Figure 6C and D).
Our in silico model predicted GBM4, SK262, SK429,
SK748 and SK1035 to be resistant to celecoxib; these pre-
dictions matched with in vitro results. However, GBM8,
SK102 and SK987 were predicted to show moderate sensi-
tivity to celecoxib, but were found to be resistant in vitro
(Figure 6E and F). For pitavastatin, the simulation pre-
dicted 5 patient-derived GBM cell lines to be sensitive
(GBM8, GBM4, SK102, SK262 and SK987), of which
SK987 was found to be resistant in vitro. On the other
Figure 6 (See legend on next page.)
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Figure 6 In silico modeling and experimental in vitro data for drug responsiveness to different drugs. This figure demonstrates in silico
predictions of sensitivity and in vitro viability in response to treatment of patient-derived GBM cell lines with A, B, bortezomib, C, D, everolimus,
E, F, celecoxib, and G, H, pitavastatin. All drugs were tested in vitro at 1 μM for 72 h and viability was assayed using Alamar Blue assay. Cells
showing decrease in viability of 20% or greater are considered sensitive to the drug.
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SK748 and SK1035), SK1035 was sensitive in vitro and did
not match with the prediction (Figure 6G and H).
These data demonstrate a 76.25% agreement between
in silico predictions of drug response and in vitro experi-
mental data in patient-derived GBM cell lines.Discussion
Developing an in silico model that takes into account
the complex genotypes/phenotypes of cancer to accur-
ately predict drug response will help personalize therapy
with more efficiency. In this study, we developed and
validated a virtual tumor model by retrospectively test-
ing it against a dataset from a recent screening study
[23]; we obtained a corroboration of ~85% between our
predictions and the results from this study. Following
this retrospective validation, we generated in silico pre-
dictions to prospectively test the sensitivity of patient-
derived GBM cell lines to targeted agents. These analyses
also demonstrated a high degree of agreement (>75%) be-
tween in vitro experimental findings and in silico predic-
tions. These studies validate our in silico tumor model
and the simulation-based approach and provide critical
proof-of-concept of a priori prediction of responses to tar-
geted therapies. Thus, this model provides an effective
platform for testing and developing personalized thera-
peutic regimens for cancer patients.
The genomic inputs that we used to create simulation
avatars for patient-derived GBM cell lines were copy
number variation data. A more comprehensive and ac-
curate profile would require additional data (gene muta-
tions, methylation status etc. along with copy number
variation); this would help us develop a more representa-
tive avatar and would likely improve the accuracy of our
drug response predictions and provide higher correlation
with experimental data.
Genotypes of cancer cell lines have traditionally been
used to correlate with drug sensitivity [28,29]. A similar
recent study makes efficient use of gene expression pro-
files to categorize colorectal cancers into different mo-
lecular and clinically actionable subtypes [30]. Moreover,
it is clear that using molecular tumor profiles to stratify
patients for therapy affects response and progression-
free survival [31]. However, increasing amounts of data
from genomic, proteomic, transcriptomic and metabolo-
mic profiling will likely require integration of these var-
ied datasets and development of predictive systemsmodeling, which may hold the key to effective cancer
therapy.
Rapid screening of patient samples in real time with
models such as the one we have developed can drive crit-
ical therapeutic decision-making. Although our current
model makes only cell-intrinsic predictions, we have been
able to achieve a high rate of agreement between in silico
predictions and in vitro findings. Future versions of this
model are being refined to incorporate tumor microenvir-
onment including aspects of angiogenesis, hypoxia, and
tumor-associated inflammation. We believe that incorpor-
ating these features into our model would more accurately
represent the tumor in a patient. Importantly, this will fur-
ther help improve our predictions for designing thera-
peutic regimens for GBM patients. This model can also be
adapted to identify potential mechanisms of resistance a
priori and to design rational drug combinations that pre-
vent emergence of resistance and development of escape
pathways.
Our in silico model aligns with NCI guidelines that
emphasize evaluation of similar predictor models to de-
termine their accuracy [12,15,32,33]. We intend to test
this model in clinical trials and utilize it as a tool to ex-
pedite clinical decision-making and determine drugs/
combinations most likely to benefit a patient. Addition-
ally, models such as these will play important roles in
testing new biological hypotheses. This is critical to the
discovery of molecular drivers and critical networks in
cancer pathophysiology and the development of better
diagnostics and effective therapeutics.
Additional file
Additional file 1: Supplementary Information.
Competing interests
The following authors are employed by Cellworks, Inc.: Zeba Sultana, Taher
Abbasi, Shweta Kapoor, Ansu Kumar, Shahabuddin Usmani, Ashish Agrawal,
and Shireen Vali. The other authors report no competing financial interests.
Authors’ contributions
SCP – designed study, performed research, analyzed data, wrote manuscript;
ZS – executed simulation studies, analyzed data, wrote manuscript; SP – designed
study, performed research, analyzed data, wrote manuscript; PJ – performed
research, analyzed data; RM – performed research, analyzed data; YC – performed
research, analyzed data; ISB – performed research; NN – performed
research; MM – performed research, analyzed data; TA – analyzed data,
developed analytics, wrote manuscript; SK – developed predictive
simulation-based tumor cell technology; AK – developed predictive
simulation-based tumor cell technology; SU – executed simulation studies,
developed predictive simulation-based tumor cell technology; AA – developed
predictive simulation-based tumor cell technology; SV – analyzed data,
Pingle et al. Journal of Translational Medicine 2014, 12:128 Page 12 of 13
http://www.translational-medicine.com/content/12/1/128developed predictive simulation-based tumor cell technology, developed
analytics, wrote manuscript; SK (Santosh Kesari) – designed study,
planned and directed research, analyzed data, wrote manuscript. All authors
read and approved the final manuscript.
Acknowledgments
This work was supported in part by grants from National Brain Tumor
Society (NBTS) David Cook Chair of Research, Barbara and Joseph Ajello trust
fund, Tuttleman Family Foundation, MCJ Amelior Foundation, and Boston
Fire Department/Kenney Foundation to S. Kesari.
Author details
1Translational Neuro-Oncology Laboratories, Moores Cancer Center, UC San
Diego, La Jolla, CA 92093, USA. 2Cellworks Research India Ltd, Bangalore 560
066, India. 3Cellworks Group Inc, Saratoga, CA 95070, USA. 4Department of
Neurosciences, UC San Diego, La Jolla, CA 92093, USA.
Received: 14 January 2014 Accepted: 23 April 2014
Published: 21 May 2014
References
1. Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 2008,
359:492–507.
2. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ,
Palotie A, Liau LM, Cloughesy TF, Nelson SF: Identification of molecular
subtypes of glioblastoma by gene expression profiling. Oncogene 2003,
22:2361–2373.
3. TCGA: Comprehensive genomic characterization defines human
glioblastoma genes and core pathways. Nature 2008, 455:1061–1068.
4. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR,
Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P,
Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG,
James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP,
Gray JW, Meyerson M, et al: Integrated genomic analysis identifies clinically
relevant subtypes of glioblastoma characterized by abnormalities in
PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98–110.
5. Deisboeck TS: Personalizing medicine: a systems biology perspective. Mol
Syst Biol 2009, 5:249.
6. Deisboeck TS, Zhang L, Yoon J, Costa J: In silico cancer modeling: is it
ready for prime time? Nat Clin Pract Oncol 2009, 6:34–42.
7. Woodward DE, Cook J, Tracqui P, Cruywagen GC, Murray JD, Alvord EC
Jr: A mathematical model of glioma growth: the effect of extent of
surgical resection. Cell Prolif 1996, 29:269–288.
8. Tracqui P, Cruywagen GC, Woodward DE, Bartoo GT, Murray JD, Alvord EC
Jr: A mathematical model of glioma growth: the effect of chemotherapy
on spatio-temporal growth. Cell Prolif 1995, 28:17–31.
9. Zhang L, Wang Z, Sagotsky JA, Deisboeck TS: Multiscale agent-based cancer
modeling. J Math Biol 2009, 58:545–559.
10. Deisboeck TS, Wang Z, Macklin P, Cristini V: Multiscale cancer modeling.
Annu Rev Biomed Eng 2011, 13:127–155.
11. Almine JF, Wise SG, Hiob M, Singh NK, Tiwari KK, Vali S, Abbasi T, Weiss AS:
Elastin sequences trigger transient proinflammatory responses by
human dermal fibroblasts. FASEB J 2013, 27:3455–3465.
12. Barve A, Gupta A, Solapure SM, Kumar A, Ramachandran V, Seshadri K, Vali S,
Datta S: A kinetic platform for in silico modeling of the metabolic dynamics
in Escherichia coli. Adv Appl Bioinform Chem 2010, 3:97–110.
13. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G,
Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC,
Anderson KC, Raje N: Dual inhibition of akt/mammalian target of rapamycin
pathway by nanoparticle albumin-bound-rapamycin and perifosine induces
antitumor activity in multiple myeloma. Mol Cancer Ther 2010, 9:963–975.
14. Equils O, Nambiar P, Hobel CJ, Smith R, Simmons CF, Vali S: A computer
simulation of progesterone and Cox2 inhibitor treatment for preterm
labor. PLoS One 2010, 5:e8502.
15. Harvey LE, Kohlgraf KG, Mehalick LA, Raina M, Recker EN, Radhakrishnan S,
Prasad SA, Vidva R, Progulske-Fox A, Cavanaugh JE, Vali S, Brogden KA:
Defensin DEFB103 bidirectionally regulates chemokine and cytokine
responses to a pro-inflammatory stimulus. Sci Rep 2013, 3:1232.
16. Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T,
Kapoor S, Sharma A, Kumar AP, Chng WJ, Sethi G: Celastrol inhibits
proliferation and induces chemosensitization through down-regulationof NF-kappaB and STAT3 regulated gene products in multiple myeloma
cells. Br J Pharmacol 2011, 164:1506–1521.
17. Kaushik P, Gorin F, Vali S: Dynamics of tyrosine hydroxylase
mediated regulation of dopamine synthesis. J Comput Neurosci
2007, 22:147–160.
18. Tandon R, Kapoor S, Vali S, Senthil V, Nithya D, Venkataramanan R, Sharma A,
Talwadkar A, Ray A, Bhatnagar PK, Dastidar SG: Dual epidermal growth factor
receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a
novel approach for overcoming resistance in anticancer treatment. Eur J
Pharmacol 2011, 667:56–65.
19. Vali S, Mythri RB, Jagatha B, Padiadpu J, Ramanujan KS, Andersen JK, Gorin
F, Bharath MM: Integrating glutathione metabolism and mitochondrial
dysfunction with implications for Parkinson's disease: a dynamic model.
Neuroscience 2007, 149:917–930.
20. Vali S, Pallavi R, Kapoor S, Tatu U: Virtual prototyping study shows
increased ATPase activity of Hsp90 to be the key determinant of cancer
phenotype. Syst Synth Biol 2010, 4:25–33.
21. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni
C, Dimeco F, Vescovi A: Isolation and characterization of tumorigenic,
stem-like neural precursors from human glioblastoma. Cancer Res 2004,
64:7011–7021.
22. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW,
Christopher N, Zhang W, Park JK, Fine HA: Tumor stem cells derived from
glioblastomas cultured in bFGF and EGF more closely mirror the
phenotype and genotype of primary tumors than do serum-cultured cell
lines. Cancer Cell 2006, 9:391–403.
23. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW,
Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L,
Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR,
Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H,
Richardson L, Zhou W, Jewitt F, et al: Systematic identification of genomic
markers of drug sensitivity in cancer cells. Nature 2012, 483:570–575.
24. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH,
Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC: Distinct sets of genetic
alterations in melanoma. N Engl J Med 2005, 353:2135–2147.
25. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J,
Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y,
Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A,
Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C,
Shipley J, et al: Mutations of the BRAF gene in human cancer. Nature 2002,
417:949–954.
26. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M,
Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC,
Slamon DJ: Activity of the dual kinase inhibitor lapatinib (GW572016)
against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Cancer Res 2006, 66:1630–1639.
27. Yost SE, Pastorino S, Rozenzhak S, Smith EN, Chao YS, Jiang P, Kesari S,
Frazer KA, Harismendy O: High-resolution mutational profiling suggests
the genetic validity of glioblastoma patient-derived pre-clinical models.
PLoS One 2013, 8:e56185.
28. Shoemaker RH, Monks A, Alley MC, Scudiero DA, Fine DL, McLemore TL,
Abbott BJ, Paull KD, Mayo JG, Boyd MR: Development of human tumor
cell line panels for use in disease-oriented drug screening. Prog Clin Biol
Res 1988, 276:265–286.
29. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW,
Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW,
Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B,
Viswanadhan VN, Johnson GS, Wittes RE, Paull KD: An information-intensive
approach to the molecular pharmacology of cancer. Science 1997,
275:343–349.
30. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ,
Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B,
Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D: A colorectal
cancer classification system that associates cellular phenotype and
responses to therapy. Nat Med 2013, 19:619–625.
31. Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S,
Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E,
Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R:
Pilot study using molecular profiling of patients’ tumors to find potential
targets and select treatments for their refractory cancers. J Clin Oncol 2010,
28:4877–4883.
Pingle et al. Journal of Translational Medicine 2014, 12:128 Page 13 of 13
http://www.translational-medicine.com/content/12/1/12832. Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S,
Sharma A, Kumar AP, Hui KM, Sethi G: Suppression of signal transducer and
activator of transcription 3 activation by butein inhibits growth of human
hepatocellular carcinoma in vivo. Clin Cancer Res 2011, 17:1425–1439.
33. Sultana Z, Paleologou KE, Al-Mansoori KM, Ardah MT, Singh N, Usmani S,
Jiao H, Martin FL, Bharath MM, Vali S, El-Agnaf OM: Dynamic modeling
of alpha-synuclein aggregation in dopaminergic neuronal system
indicates points of neuroprotective intervention: experimental
validation with implications for Parkinson's therapy. Neuroscience
2011, 199:303–317.
doi:10.1186/1479-5876-12-128
Cite this article as: Pingle et al.: In silico modeling predicts drug
sensitivity of patient-derived cancer cells. Journal of Translational Medicine
2014 12:128.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
